RYTM
Rhythm Pharmaceuticals Inc.
Halal Rating :
Last Price
$54.61
Last updated:
Market Cap
-
7D Change
-0.51%
1 Year Change
30.93%
Company Overview
Industries
Exchange
Next Earnings Date
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic diseases of obesity. Their lead product is IMCIVREE® (setmelanotide), which is approved for chronic weight management in patients with specific genetic conditions affecting the melanocortin-4 receptor (MC4R) pathway.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $33.25m | $82.38m | - | $5.24m | 0.00% | 6.36% |
| June 30, 2024 | $29.08m | $74.16m | - | $4.6m | 0.00% | 6.21% |
| March 31, 2024 | $25.97m | $170.61m | - | $4.75m | 0.00% | 2.79% |
Company Impact
Help us evaluate Rhythm Pharmaceuticals Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.